BC Platforms and OmicsBank launch collaboration to grow real-world and multi-omics evidence from India and the UAE

BC Platforms and OmicsBank have launched a joint initiative to expand access to longitudinal clinical and multi-omics real-world data (RWD) from India and the UAE, increasing emerging-market representation in global research and supporting more robust evidence generation across precision medicine, regulatory, and reimbursement use cases.

BC Platforms has entered into an agreement with OmicsBank to add large-scale, research-ready datasets from India and the UAE to its global network, with the aim of improving representation of South Asian populations in evidence generation and supporting more globally applicable real-world evidence (RWE) strategies.

Under the agreement, BC Platforms’ global patient network will expand by more than 12 million patient lives from India and around 500,000 from the UAE. The combined datasets include electronic medical records, pathology slides, medical images, sequencing data, and linked biospecimens. According to the companies, these can be provisioned either as modular datasets for specific research use cases or as longitudinal cohorts for broader analytics and multimodal AI model development.

The collaboration will also integrate OmicsBank data into BC Platforms’ existing platforms, including BC Unify for data mastering, BC Mosaic for federated trusted research environments, and BC Catalyst for analytics and predictive insights.

With OmicsBank added, BC Platforms’ network now provides access to more than 187 million patient lives across over 35 countries. The company also signaled planned expansion into additional markets, including Saudi Arabia, Taiwan, the Philippines, and Malaysia, as OmicsBank broadens its hospital and diagnostic laboratory partnerships.

This collaboration reflects a broader push for more representative RWD in genomics and clinical research. India accounts for nearly one-fifth of the global population and has substantial genetic and disease diversity, yet South Asian populations remain underrepresented in many genome-wide association studies. As regulators, HTA bodies, and payers increasingly require robust RWE for feasibility, safety, and effectiveness assessments, evidence built mainly on US and European datasets may be less transferable across populations. Expanding access to high-quality Indian patient data can help reduce the potential for Western-centric bias and support more globally relevant evidence-generation and development strategies.

Mukhtar Ahmed, CEO of BC Platforms, said India’s large and diverse population “makes it invaluable from a scientific and regulatory perspective – and critical for life science companies that are seeking innovative targeted therapies and pursuing precision medicine strategies,” adding that the collaboration will help customers “better understand, develop and launch novel therapies” for distinct patient populations. Sumit Sinha, CEO of OmicsBank, said the work with BC Platforms “allows us to extend this capability globally and help ensure that diverse patient populations are more accurately represented across the drug development lifecycle.”